
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$35.13
−US$0.02 · -0.06%
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
常规交易时段
US$35.13
−US$0.02 · -0.06%
盘中时间采用ET。市场数据可能有所延迟。
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
日内区间
当前US$35.13
52周区间
当前US$35.13
盘中时间采用ET。市场数据可能有所延迟。
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
日内区间
当前US$35.13
52周区间
当前US$35.13
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.03亿 USD | 8667.24万 USD | 6498.98万 USD | 4584.28万 USD | 2414.39万 USD |
| 销货成本 | 1018.28万 USD | 813.99万 USD | 785.27万 USD | 636.09万 USD | 231.12万 USD |
| 毛利 | 9293.51万 USD | 7853.25万 USD | 5713.72万 USD | 3948.2万 USD | 2183.27万 USD |
| 研究与开发 | 507.25万 USD | 570.34万 USD | 413.24万 USD | 336.7万 USD | 55.87万 USD |
| 销售、一般及管理费用 | 7871.7万 USD | 7655.99万 USD | 5699.48万 USD | 4597.63万 USD | 2805.32万 USD |
| 营业费用 | 8378.95万 USD | 8524.8万 USD | 6135.23万 USD | 5199.92万 USD | 2920.89万 USD |
| 利息收入 | 3672 USD | 2.2万 USD | — | 28.47万 USD | — |
| 利息支出 | 675.98万 USD | 312.84万 USD | 47.58万 USD | 28.47万 USD | 711 USD |
| 折旧和摊销 | 2855.8万 USD | 492.32万 USD | 367.5万 USD | 237.11万 USD | 59.7万 USD |
| 营业利润 | 914.57万 USD | −671.55万 USD | −421.52万 USD | −1251.72万 USD | −737.62万 USD |
| 净利润 | −3756.26万 USD | −966.45万 USD | −430.32万 USD | −793.75万 USD | −792.19万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
评级样本有限,仅3项
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息即将实施 | 2027年7月29日 | US$33.00Irregular | — | — |
除息 2027年7月29日
US$33.00
Irregular
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI519.36万0.00%2.3万亿 USD0.03%US$381.51-0.02%
iShares Russell 2000 ETFIWM427.3万0.01%787.4亿 USD0.19%US$277.07-0.30%
iShares Russell 2000 Growth ETFIWO153.92万0.01%139.17亿 USD0.24%US$351.66-0.58%
Vanguard Extended Market ETFVXF149.51万0.00%954亿 USD0.05%US$232.81-0.30%
Fidelity Enhanced Small Cap ETFFESM91.56万0.01%64.1亿 USD0.28%US$45.16-0.18%
Vanguard Russell 2000 ETFVTWO68.17万0.00%180亿 USD0.06%US$111.91-0.32%
iShares Micro-Cap ETFIWC54.78万0.04%13.17亿 USD0.60%US$180.24-0.78%
Avantis U.S. Small Cap Equity ETFAVSC26.05万0.01%30.79亿 USD0.25%US$70.13+0.23%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXF
Fidelity Enhanced Small Cap ETFFESM
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Avantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。